Current oncological treatment for patients with locally advanced lung cancer comprise adjuvant immunotherapy (immune checkpoint inhibitors-ICI) as an additional one-year treatment after chemoradiotherapy which increases overall survival and progression-free survival. Patients with lung cancer have a high burden of distressful symptoms at diagnosis and during chemoradiotherapy. Side-effects from immunotherapy differs, they are unspecific and may develop at any point during treatment. However, it is not investigated thoroughly during adjuvant treatment in locally advanced lung cancer. As new oncological treatments are being introduced, focus must be placed on patients quality of life and how patients endure treatment to be able to know how to best support patients during this treatment. The knowledge gained from this project include how adjuvant immunotherapy treatment impacts health. This knowledge is sparse due to the novelty of the treatment.
Patients with locally advanced non-small lung cancer
cared for at either one of two specialized oncology centres
≥ 18 years of age
planned for concurrent chemoradiotherapy including ICI for 12 months
diseases or comorbidities that may have significant impact on the outcome variables
limited understanding of the Swedish language preventing the possibility to give oral and written informed consent.
Göteborg University
Lead sponsor
Västra Götalandsregionen
Collaborator
Region Jönköping County
Collaborator